Changes in the structure of the proteoglycan aggrecan (PG) of articular cartilage were determined immunochemically by RIA and gel chromatography and related to cartilage degeneration documented histologically by the Mankin grading system. Monoclonal antibodies to glycosaminoglycan epitopes were used. In all cartilages, three chondroitin sulfate (CS)-rich populations of large size were observed in addition to a smaller keratan sulfate (KS)-rich population. In grades 7-13 OA cartilages (phase II), molecules were significantly larger than the equivalent molecules of grades 2-6 (phase I). CS chain lengths remained unchanged. In most OA cartilages, a CS epitope 846 was elevated in content, this being most marked in phase II (mean: fivefold). Loss of uronic acid, KS, and hyaluronic acid were only pronounced in phase II OA because of variations in normal contents. Aggregation of PG was unchanged (50-60%) or reduced in OA cartilages, but molecules bearing epitope 846 exhibited almost complete aggregation in normal cartilages. This study provides evidence for the capacity of OA cartilage to synthesize new aggrecan molecules to replace those damaged and lost by disease-related changes. It also defines two phases of PG change in OA: an early predominantly degenerate phase I followed by a net reparative phase II accompanied by net loss .of these molecules. (J. Clin. Invest. 1992. 90:2268-2277
Introduction
Osteoarthritis is a degenerative joint disease that involves impairment and eventually loss ofjoint function. It is characterized by extensive degeneration of the articular cartilages in both large and small joints, usually in the presence of low level intraarticular inflammation (1) .
The articular cartilage ofa diarthrodial joint is composed of an extensive network of collagen fibrils that provide cartilage with its tensile strength and stiffness (2, 3) . This is composed predominantly of type II collagen. Type XI collagen is present within the fibril (4). On its surface, covalently attached to type II collagen in the nonhelical telopeptide regions, resides type IX collagen (5, 6) . Interacting with this network, either directly or indirectly, is a "mesh work" of high molecular weight hyaluronic acid (HA)' (7) . A large proteoglycan (PG), called aggrecan, which on synthesis has a 2-4 X 106 Mr, binds to HA through an amino-terminal GI globular domain (8) . Each attachment is stabilized by a single link protein (9, 10) that shares sequence homology with the G 1 domain (1 1, 12) .
The core protein of aggrecan contains a second globular domain called G2 which has considerable homology with GI ( 12) : its function is unknown. Between G2 and another globular domain called G3 (12, 13) situated at the carboxyl-terminal, there are the glycosaminoglycan attachment regions ( 12, 13) . Adjacent to G2 there is a keratan sulfate (KS) attachment region composed of repeating hexapeptide motif and containing up to 30 KS chains ( 13, 14) . Between this region and G3 there is a high concentration of up to 100 CS chains ( 13 ) . There is evidence from studies ofhuman aggrecan, based on core protein structure, that this region may be composed of two subdomains called CS-I and CS-2 (13) . The G3 domain has been shown to have lectin-like properties, since it binds to galactosyl residues ( 15) . This property may permit interactions with molecules in the extracellular matrix.
Antibodies have been prepared to unsaturated sulfated and unsulfated disaccharides of chondroitin sulfate (CS), some of which remain as stubs attached to the core protein of aggrecan after eliminative digestion of CS ( 16, 17) . These antibodies react preferentially with the "stubs" that remain attached to core protein, and are sulfation specific (disaccharide chondroitin 4-sulfate stubs attached to core protein [AdiC4S-s], disaccharide chondroitin 6-sulfate stubs attached to core protein , and disaccharide chondroitin stubs attached to core protein [AdiCOS-s] ). More recently, antibodies to native CS epitopes have been prepared ( 16, 18, 19) . These are usually most commonly found in fetal or embryonic tissues. The majority ofthe epitopes they recognize remain to be characterized. Antibodies to KS (20, 21 ) have been shown to recognize highly sulfated domains on this glycosaminoglycan (22) . Use ofthese antibodies in immunoassays permits the detection and measurement of PG and fragments thereofin cartilages in the presence of other macromolecules ( 17) .
These proteoglycans constitute up to 10% ofthe wet weight of cartilage. Because of their high content of glycosaminoglycans, they become very hydrated and can absorb up to 50 times their weight of water. But this hydration is constrained by the tensile strength of the collagen network. This results in a swelling or osmotic pressure that endows cartilage with its compressive stiffness and hence its reversible deformability (23) (24) (25) . As human articular cartilage ages, there is an accumulation of the G I globular domain (26) and ofsmaller KS-rich aggrecan molecules (27, 28) . These proteoglycan degradation products increase in content mainly in the deep zone (28, 29) . The degradation probably occurs over a period of time in the extracellular matrix. Further evidence for extracellular degradation is provided by the progressive accumulation with aging of link protein of reduced size (30) . This probably results in part from the extracellular action of proteinases, such as the metalloproteinase stromelysin (31 ) .
There have been many studies ofthe PG aggrecan in osteoarthritic articular cartilages. These have sometimes produced contradictory results. Studies ofmolecular size and aggregation with HA invariably involved measurement of uronic acid or hexosamine content. These investigations concluded that there is either no change (32), a reduction (33, 34) , or an increase (35) in molecular size in osteoarthritis (OA). Loss of aggregation in advanced disease has been reported (36), but others found no change in aggregation (32) . There is, however, a reduction in KS relative to CS content (33) . Synthesis is often increased in early degeneration and later decreased as cartilage is further destroyed (37, 38) . These observations indicate that there are significant changes in this PG in OA, but the precise molecular events involved and implications of these changes are unclear, since these studies were made on many different specimens, concentrating on chemical analyses of the chondroitin sulfate of isolated high buoyant density PG. Moreover, in most of these studies, with a few exceptions in which synthesis was studied (37, 38) , there was a failure to relate molecular changes to the different stages of degenerative change that Mankin et al. have described (38) . Cartilages were usually inappropriately treated as a homogeneous group.
We therefore decided to use newly developed quantitative immunochemical assays for the study of these molecules in total cartilage extracts so that aggrecan size, heterogeneity, composition, degradation products, and aggregation could be clearly identified in normal and OA cartilages that had been age-and tissue-matched and histologically graded for degenerative changes. The study presented here provides evidence for even more molecular heterogeneity than has been previously recognized. It also reveals biosynthetic and degradative changes in OA that are indicative of an initial phase of net degradation followed by a phase of extensive replacement with new aggrecan molecules that are then partially degraded: Eventually, there is a net loss ofthese molecules in advanced disease.
Methods
Cartilage. Human Histology. A full depth sample adjacent to the specimen chosen for immunochemical and biochemical analyses was removed and fixed for 24 h in 10% formalin in 25 mM sodium phosphate, pH 7.0, for histology. After wax embedding, 6-Am thick sections taken at two different levels perpendicular to the articular surface were cut and stained with hematoxylin and eosin or with safranin-O and fast green-iron hematoxylin. Sections were graded according to Mankin's histological grading system for OA cartilages (38) . This method assigned scores to the intactness of the structure of the tissue, the sizes and grouping of the cells and the degree of safranin-O (proteoglycan) staining. The scores were totaled for each sample and a grade was assigned. Since sections were cut up to, but not including the tide mark, this was excluded from the grading. The maximum score possible, when tide mark is not included, is 13.
Extraction ofPG. The 20-Atm thick frozen sections from each sample were extracted with 30 vol (wt/vol) of 4 M guanidinium chloride (GuCl) in 100 mM sodium acetate, pH 6.0 (containing 1 mM EDTA, 1 mM iodoacetic acid, 1 mM phenylmethylsulphonyl fluoride with 5 ,ug/ml of pepstatin to inhibit metallo, cysteine, serine, and aspartate proteinases, respectively) at 4°C for 48 h with constant stirring. The PG extracts were clarified by centrifugation in a Sorval GLC-2B centrifuge at 3,500 rpm (2,000 g) for 15 min to remove any particulate material. Supernatant and pellet were stored separately at -20°C. Before assay for uronic acid (see below) pellets were rinsed with distilled water, dissolved in 2 ml 7 N HCl and incubated at 70°C for 20 min.
Isolation andpurification ofproteoglycan standardsfor radioimmunoassays. Aggrecan monomer was prepared from extracts of fetal and adult cartilages (10 vol Immunoassays. Radioimmunoassays were performed using antibodies to KS (AN9P1 ) (21, 27) , and to unsaturated disaccharides produced by digestion of CS with chondroitinase ABC, namely AdiC4S-s monoclonal 6B ( 17) and AdiC6S-s (monoclonal 3B33) (16) . A mouse monoclonal antibody 846 was used that reacts with an as yet unidentified fetal-common epitope on the native CS of aggrecan (chondroitinase ABC labile) (Poole, A. R., and A. Reiner, unpublished observation) and not on core protein as previously concluded ( 18) . The radioimmunoassays were as described previously for AN9P1 (27) , 6B (17) , and 846 (18) . These used both '25I-labeled and unlabeled (for tracer and standard, respectively) human fetal (846 and 6B) and adult (AN9P1 and 3B3) human aggrecan. Chondroitinase ABCtreated aggrecan ( 17) Mon- treal) at 10% (wt/wt) of the PG content (the proteoglycan content in extracts of adult cartilage was estimated as being 6.5 times the total uronic acid (UA) content, which is about 15% ofthe total proteoglycan for this age group [ 39] ), was added to the PG extract in 4 M GuCl. The The OA group is divided into phase I OA (Mankin grade < 6) and phase II OA (Mankin grade 2 7) . From some joints two specimens were taken (a and b). * Significant when compared with normals (P < 0.05). (mean 68.6±8.7 SD), the percentage extracted from OA cartilage with grades . 6 (mean 69.8±5.4 SD) and grades 7-13 (mean 73.2±8.4 SD) did not change.
Total content of extractable proteoglycan epitopes, uronic acid and HA in normal and osteoarthritic cartilages and Mankin grade. The need to use different PG standards (fetal and adult), prevented a comprehensive analysis of the absolute compositions ofthe different molecules identified in this study. But these analyses did permit comparisons to be made of the relative content of fetal epitopes (AdiC4S-s and 846), adult epitopes (AdiC6S-s and KS), and epitope differences between healthy and OA cartilages. There were differences in epitope contents when samples from different sites on the same femoral condyles were examined. But these contents were often recognizably different from those in OA cartilages. In OA cartilages, several trends (Fig. 2 ) and significant differences (Table  II) were observed. UA content, AdiC6S-s, KS, and HA contents tended to decrease, whereas AdiC4S-s and epitope 846 increased with Mankin grade (Fig. 2) . To permit a clearer analysis, these changes in OA were classified as phase I (grades 2-6) or phase II OA (grades 7-12) (Table II) . Chondroitin 6-sulfate stubs were significantly decreased in phase II more than in phase I. Keratan sulfate and HA contents were also significantly reduced in phase II more than in phase I when compared with normals. Uronic acid content was not significantly changed in phase I and phase II OA. AdiC4S-s and epitope 846 were significantly increased in both phase I and II when compared with normals. These observations clearly reveal compositional changes in OA cartilages that are related to the degree of degeneration revealed by histological grading. Fig. 3 , and representative OA samples are shown in Fig. 4 . These analyses revealed the presence of different populations of PG in normal and OA cartilages characterized by differences in composition and size. For example, in normal cartilage, the largest population eluted at a Kav y 0.35. It was recognized using the anti-AdiC6S-s antibody. Eluting at approximately the same Kav, and present in a relatively very small amount was a population bearing epitope 846. Slightly smaller than the AdiC6S-s population was a population eluting at Kav -0.45. This was recognized by the antiAdiC4S-s antibody, 6B. This suggests that the AdiC4S-s population is smaller than and distinct from the AdiC6S-s and epitope 846 population(s). Eluting at Kav y 0.6 was a PG population recognized by the anti-KS antibody, AN9P1. This is the small KS-rich PG population previously described by us (27) recognized as a degradation product ofaggrecan containing the KS-rich region. In general, the elution for AdiC6S, AdiC4S, and 846 was often but not always unimodal. A small "shoulder" of higher molecular weight PG was seen in the elution profile for KS. Similar populations were identified in OA cartilages, irrespective of grade.
To compare these populations in normal and OA cartilages, the following approach was used as outlined in Fig. 5 . The relative contents of epitopes in column fractions less or greater than a given Kav, which was fixed for each epitope in normal and OA cartilages, were determined and expressed as a percentage ofthe total epitope content in all column fractions. Therefore, for epitopes AdiC6S-s, 846, and AdiC4S-s (Kav < 0.35) and for KS (Kav 2 0.55), relative hydrodynamic sizes were calculated as percentages. These results are shown in Table III. The data shown are therefore for the percentage amount of a PG of a given hydrodynamic size. Examination of the different populations in normal cartilages confirmed the presence of two populations of similar size containing zAdiC6S-s and 846 epitopes. These were significantly larger than the population containing AdiC4S-s (Table III) . The presence of a much smaller KS-rich population is again apparent.
When the sizes of the different PG in all the OA samples were compared with the normal samples, there was no evidence for any significant differences. But when the OA specimens were divided into two groups by their grades, phase I (grade < 6) and phase II (grades 2 7), significant differences were observed (Table III) . The equivalent PG proteoglycans in phase I OA were generally smaller than in normal cartilage but the differences were not significant. But in phase II OA, molecules bearing epitopes AdiC6S-s, 846 , and AdiC4S-s were significantly larger in size than the corresponding PG in phase I OA (grades 7-13). The predominant small KS-rich PG species showed no significant changes (Table III) Fig. 6 . There was no evidence for any change in chain length in OA cartilage of various Mankin grades.
Monomer aggregation. Analysis ofthese populations under associative conditions revealed that in normal cartilages, between 50 and 59% of each of these populations aggregated with the exception of the population identified by epitope 846, which showed almost complete aggregation (Table IV, Fig. 7) . Therefore, there exist two populations of the largest size, one identifiable by the AdiC6S-s stubs on core protein and a more minor population bearing epitope 846. Analysis of aggregation of PG from OA cartilages with HA revealed similar aggregation for AdiC6S-S and KS epitopes to that seen in normal cartilage (Table IV) . But (37, 38) . This loss of synthesis accompanied a net loss ofPG that was only clearly observed in advanced disease. Using this approach, we examined PG size, composition, aggregation, and content as the disease progresses.
All our PG populations were observed in OA cartilage irrespective of grade. However, the aggregation differences between the populations bearing epitope 846 and AdiC6S-s were no longer observed. Changes were noted in these two epitopes indicative ofchanges in CS composition. AdiC6S-s content was reduced, whereas epitope 846 and AdiC4S-s contents were increased. This probably occurred when there was no overall change in uronic acid content, although KS content was reduced. The assignment oftwo phases ofOA permitted the clear recognition of pathology-related changes that have not previously been reported. In phase I, there is evidence for a general reduction (although not significant) in the sizes of all the PG populations compared to their normal counterparts. Since this is accompanied by the loss of AdiC6S-s, this may indicate the loss of the G3 and CS2 domains, according to our proposed assignment of AdiC6S-s to the CS2 domain. This reduction in size was not accompanied by a change in CS chain length, suggesting that increased proteolysis occurred involving the core protein. Moreover, the loss of aggregation shown by the population bearing epitope 846 is also indicative ofproteolysis.
In phase II ofthe disease (grades 7-13), when fibrillation is more extensive and cartilage becomes very degenerate in appearance, the CS-rich and KS-rich PG populations were still detected. But they were all larger than their normal counterparts and (except for the KS-rich molecules) were significantly larger than their phase I counterparts. These increases in size did not result from changes in CS chain length, (observed previously, reference 42), suggesting that these larger molecules contained longer core proteins and were less degraded.
Collectively, these observations indicate that in OA, two phases can be identified in the pathological changes involving aggrecan that occur in the articular cartilages. The initial phase I is characterized by a general degradation of PG molecules combined with replacement with new molecules of altered composition, as indicated earlier (37, 38) . Then in phase II there is extensive replacement of degraded molecules with larger compositionally different molecules, probably as a result of the increased synthesis described previously. Evidence for changes in the biosynthesis of CS come not only from our studies of AdiC4S-s and AdiC6S-s but also from the increase in content of the native CS epitope 846: The latter would be expected if, as we suggest, epitope 846 is present on recently synthesized molecules and is located on CS close to the G3 domain. A similar increase in content of another native CS epitope recognized by monoclonal antibody 3B3 has also been observed in experimental OA in dogs (43) . Since these native CS epitopes are most commonly found in fetal and embryonic tissues, their reappearance in OA suggests that changes in the environment of the chondrocyte cause changes in synthesis and CS assembly.
Eventually, as a result of extensive damage to the cartilage, PG is lost. This probably results from extensive damage to the collagen fibrillar organization we described previously (44) leading to the loss of HA (45, 46) and of PG (37, 38) observed in the present study as well as previously. But 
